Mesoblast (MEOBF) Net Cash Flow Growth (3y) (2017 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) Net Cash Flow Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | -36.28% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 30.02% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -63.92% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 93.57% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 21.38% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -115.96% |
| Dec 31, 2022 | -22.20% |
| Sep 30, 2022 | 75.78% |
| Mar 31, 2022 | -39.31% |
| Dec 31, 2021 | -33.57% |
| Sep 30, 2021 | -3.09% |
| Jun 30, 2021 | 0.40% |
| Mar 31, 2021 | 88.65% |
| Dec 31, 2020 | -27.14% |
| Sep 30, 2020 | -48.01% |
| Mar 31, 2020 | -34.09% |
| Dec 31, 2019 | 47.33% |
| Sep 30, 2019 | 9.21% |
| Mar 31, 2019 | 32.73% |
| Sep 30, 2018 | 41.28% |
| Mar 31, 2018 | 38.41% |
| Sep 30, 2017 | 38.00% |